FIG. 1





FIG. 2



	Bispecific Antibody #1 (control)	Bispecific Antibody #2	Bispecific Antibody #3	Bispecific Antibody #4	Bispecific Antibody #5
Max %growth inhibition	77.4	56.4	57.9	71.3	67.8
IC50(nM)	0.19	0.13	0.037	0.13	0.13

FIG. 3A



BT-474, NSG, SC axilla
Tumor Volume (mm3)
600
400
200
0
0
10
20
30
40
Days post-inoculation
80 mg/kg
(or 40 + 40 mg/kg)
IP
Ctrl IgG
Tras + Per
ATV:CLC bispecific
antibody #1

FIG. 3B



Mean Tumor volume (mm3)
OE19, NOD/SCID, SC flank
DNLI-21-112
Tumor Volume (mm3)
4000
3000
2000
1000
0
0
10
20
30
40
Days post-treatment
100 mg/kg
(or 50 + 50 mg/kg)
IP
Ctrl IgG
ATV:tras + ATV:per
ATV:CLC bispecific
antibody #1

FIG. 4A



orthotopic (MFP) BT-474, NOD/SCID
Tumor Volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
Days post-treatment
20 mg/kg IP dose
Ctrl IgG
CLC bispecific antibody control
ATV:CLC bispecific antibody #1

FIG. 4B



OE19, NOD/SCID, SC flank
Tumor Volume (mm3)
4000
3000
2000
1000
0
0
10
20
30
Days post-treatment
Single IP dose
Ctrl IgG (20 mpk)
CLC bispecific antibody control (20 mpk)
ATV:CLC bispecific antibody #1 (5 mpk)
ATV:CLC bispecific antibody #1 (20 mpk)

FIG. 5A



orthotopic (MFP) BT-474, NOD/SCID
Tumor Volume (mm3)
1500
1000
500
0
0
10
20
30
Days on study
Vehicle (n=9)
ATV:CLC bispecific antibody #2 (n=11)
ATV:CLC bispecific antibody #1 (n=11)
IP dosing Q1Wx3

FIG. 5B



OE19 SC flank, NOD SCID
Tumor Volume (mm3)
4000
3000
2000
1000
0
0
20
40
60
Days on study
Ctrl IgG (20 mpk)
Tras + Per (20 + 20 mpk)
CLC bispecific antibody control (20 mpk)
ATV:CLC bispecific antibody #3 (20 mpk)
Q2W x 3 IP dosing

FIG. 6



Brain hulgG
24 h, 25 mg/kg IV
hulgG concentration (nM)
20
15
10
5
0
CLC bispecific antibody control
ATV:CLC bispecific antibody #3

FIG. 7B




FIG. 7A




FIG. 8




Serum hulgG Concentration
50 mg/kg, single IV bolus, NHP
Traztuzumab
ATV:CLC bispecific antibody #4
ATV:CLC bispecific antibody #5
ATV:CLC bispecific antibody #6
[HulgG] in Cyno Serum (μM)
100
10
1
0.1
0
48
96
144
192
240
288
336
Timepoint (hours)
Error bar: Mean ± SEM
n=3 / group

FIG. 9


Antibody-Dependent Cell Cytotoxicity Assay
% Cytotoxicity
100
80
60
40
20
0.0001
0.001
0.01
0.1
1
10
100
1000
Concentration (nM)
Trastuzumab
CLC bispecific antibody control #2
ATV:CLC bispecific antibody #3
ATV:CLC bispecific antibody #7
ATV:CLC bispecific antibody #2
Ctrl IgG (EF+)